Events9th International Electronic Conference on Medicinal Chemistry
Published
with-doi10.3390/ECMC2023-15702 (registering DOI)
This submission belongs to the session S4. New Small molecules as drug candidates of the event 9th International Electronic Conference on Medicinal Chemistry
Published date
01 Nov, 2023
Academic Editor
author-avatarAlfredo Berzal-Herranz
Citation
Maria João Matos, Aitor Carneiro, Sela González, Cynthia N. Pereira, Alessandro Raffa, Francesca Vella, Marzia Doneddu, Dheyaa M. Dhahir, Evaluation of in vitro cytotoxic and hemolytic effects of a new series of hydroxy- and nitro-containing arylcoumarins, in Proceedings of 9th International Electronic Conference on Medicinal Chemistry, 1 November–30 November 2023, MDPI: Basel, Switzerland, doi: 10.3390/ECMC2023-15702
Share
Email
Facebook
Twitter
LinkedIn

Evaluation of in vitro cytotoxic and hemolytic effects of a new series of hydroxy- and nitro-containing arylcoumarins

Cynthia N. Pereira 2
Alessandro Raffa 2
Francesca Vella 2
Marzia Doneddu 1
image
1. Departamento de Química Orgánica, Facultad de Farmacia, Universidade de Santiago de Compostela, 15782 Santiago de Compostela, España, Spain
2. Departamento de Química Orgánica, Facultad de Farmacia, Universidade de Santiago de Compostela, 15782 Santiago de Compostela, España
3. Departamento de Química Orgánica, Facultad de Farmacia, Universidad de Santiago de Compostela, Spain
Abstract

Coumarins are natural or synthetic compounds with a variety of biological applications, from fluorescent probes to therapeutic agents. Our group has been studying the importance of this moiety in the development of drugs targeting neurodegeneration. Based on the structure of the acenocoumarol, a frequently prescribed oral anticoagulant to treat and prevent thromboembolism, nitro groups have been commonly introduced in coumarin-containing compounds. Therefore, the assessment of their safety for humans is essential.1,2

In the current work, twelve hydroxy- and nitro-substituted arylcoumarins have been synthetized, and cytotoxicity and hemolytic effects have been studied. Human embryonic kidney cells (HEK-293, strain ATCC CRL1573) and human red blood cells (RBC) have been used for the in vitro assays. Compounds were plated as a 2-fold dose response from 32 to 0.25 μg/mL, with a maximum of 0.5% DMSO. Values of CC50 (cytotoxicity) and HC10 (haemolytic activity) are presented in this communication.

(1) Martins Castanha AP, Moura Almeida-Terassi L, Guardado-Yordi E, Matos MJ, Maistro EL. Cytogenotoxicity assessment of 3-(3,4-dihydroxyphenyl)-7,8-dihydroxycoumarin on HepG2/C3A cells and leukocytes. J Appl Toxicol 2023, 43, 323−334. DOI: 10.1002/jat.4384.

(2) dos Santos Silva E, Matos MJ, Maistro EL. Evaluation of in vitro Cytotoxic and Genotoxic Effects of the 3-(3,4-Dihydroxyphenyl)-8-hydroxycoumarin. J Appl Toxicol 2023. DOI: 10.1002/jat.4479.

Keywords
cytotoxic
hemolytic effects
arylcoumarins
Manuscript
Nanoparticles Derived from Rhazya Stricta: Promising Advances for Anti-Cancer/Anti-Bacterial Treatment - In Vitro Studies
Investigation of the interaction between isopropyl derivative of thiosalicylic acid and human serum albumin